MESENCHYMAL STEM CELL AND THE METHOD OF USE THEREOF

• US 20150337265A1
• Filed: 05/28/2015
• Published: 11/26/2015
• Est. Priority Date: 06/26/2000
• Status: Active Grant

• Current Assignee: ASKA Pharmaceutical Company Limited, NC Medical Research Inc. (e-solutions, Inc. /Japan/), Mitsui Sumitomo Insurance Care Network Co., Ltd. (Ms&Ad Insurance Group Holdings Incorporated)
• Original Assignee: ASKA Pharmaceutical Company Limited, NC Medical Research Inc. (e-solutions, Inc. /Japan/), Mitsui Sumitomo Insurance Care Network Co., Ltd. (Ms&Ad Insurance Group Holdings Incorporated)
• Inventors: HONMOU, Osamu, HASHI, Kazuo, UEDE, Teiji
• Granted Patent: US 10,640,749 B2
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: A61K 2035/124 the cells being hematopoietic, bone marrow derived or blood cells
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61K 35/51 Umbilical cord; Umbilical cord blood; Umbilical stem cells
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/02 for peripheral neuropathies
• CPC Class Codes: A61P 25/08 Antiepileptics; Anticonvulsants
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C12N 2506/1353 from bone marrow mesenchymal stem cells (BM-MSC)
• CPC Class Codes: C12N 5/0622 Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
• CPC Class Codes: C12N 5/0662 Stem cells
• CPC Class Codes: C12N 5/0663 Bone marrow mesenchymal stem cells (BM-MSC)
• CPC Class Codes: C12N 5/0664 Dental pulp stem cells, Dental follicle stem cells
• CPC Class Codes: C12N 5/0665 Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
• CPC Class Codes: C12N 5/0666 Mesenchymal stem cells from hair follicles
• CPC Class Codes: C12N 5/0667 Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
• CPC Class Codes: C12N 5/0668 : Mesenchymal stem cells from other natural sources
• CPC Class Codes: C12N 5/0676 : Pancreatic cells

Abstract

Demyelinated axons were remyelinated in the demyelinated rat model by collecting bone marrow cells from mouse bone marrow and transplanting the mononuclear cell fraction separated from these bone marrow cells.

Claims

1. (canceled)

2. A cell population isolated from bone marrow or cord blood comprising mesenchymal stem cells,

wherein said mesenchymal stem cells are SH2(+), SH3(+), SH4(+), CD29(+), CD44(+), CD14(−

), CD34(−

), and CD45(−

), and

wherein cells within said cell population are capable of differentiating into neurons or glia cells.

4. A method for treating a demyelinating disorder, which comprises injecting, recipient, the cell population according to claim 2.

5. A method for treating a brain tumor, which comprises injecting, into a recipient, the cell population according to claim 2.

6. A method for treating epilepsy, which comprises injecting, into a recipient, the cell population according to claim 2.

3. A method for treating neurodegeneration, comprising

isolating a cell population from bone marrow,

wherein said cell population comprises mesenchymal stem cells that are SH2(+), SH3(+), SH4(+), CD29(+), CD44(+), CD14(−

), CD34(−

), and CD45(−

) and said isolation does not exclude hematopoietic cells from said cell population; and

injecting an effective amount of said isolated cell population into a patient in need of said treatment,

wherein said effective amount of said isolated cell population is effective at treating said patient'"'"'s neurodegeneration.

12. The method for treating neurodegeneration according to claim 3, wherein said neurodegeneration is caused by nerve demyelination.

13. The method for treating neurodegeneration according to claim 3, wherein said cell population is isolated from cord blood.

14. The method for treating neurodegeneration according to claim 3, wherein said cell population is injected intra-arterially.

15. The method for treating neurodegeneration according to claim 3, wherein said cell population is injected intravenously.

16. The method for treating neurodegeneration according to claim 14, wherein said cell population is injected into the carotid artery.

17. The method for treating neurodegeneration according to claim 3, wherein cells within said injected cell population are capable of differentiating into neuron or glia cells.

18. The method for treating neurodegeneration according to claim 3, wherein said neurodegeneration is caused by ischemia.

19. The method for treating neurodegeneration according to claim 18, wherein said neurodegeneration caused by ischemia is stroke.

20. The method for treating neurodegeneration according to claim 3, wherein said neurodegeneration is caused by demyelination or trauma.

21. The method for treating neurodegeneration according to claim 20, wherein said trauma is caused by spinal cord injury or brain injury.

22. The method for treating neurodegeneration according to claim 20, wherein said demyelination is caused by spinal cord injury or multiple sclerosis.

23. The method for treating neurodegeneration according to claim 3, wherein said neurodegeneration is associated with Alzheimer'"'"'s disease, Parkinson'"'"'s disease, Huntington'"'"'s disease, or amyotrophic lateral sclerosis (ALS).

7. A mononuclear cell fraction comprising cells capable of differentiating into neurons or glia cells, wherein said fraction is prepared by

obtaining bone marrow cells or cord blood cells,

diluting the bone marrow cells,

separating a mononuclear cell fraction,

collecting said mononuclear cell fraction.

8. A method for treating a neurodegenerative disorder, which comprises injecting, into a recipient, the mononuclear cell fraction according to claim 7.

9. A method for treating a demyelinating disorder, which comprises injecting, into a recipient, the mononuclear cell fraction according to claim 7.

10. A method for treating a brain tumor, which comprises injecting, into a recipient, the mononuclear cell fraction according to claim 7.

11. A method for treating epilepsy, which comprises injecting, into a recipient, the mononuclear cell fraction according to claim 7.